Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-human Study of Safety, Tolerability, and Pharmacokinetics of VX-668

NCT05727800 is registered in ClinicalTrials.gov with Vertex Pharmaceuticals Incorporated as lead sponsor.

NCT NCT05727800
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05727800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-human Study of Safety, Tolerability, and Pharmacokinetics of VX-668
Lead sponsor
Vertex Pharmaceuticals Incorporated
Phase
Phase 1
Overall status
Completed
Start date
February 8, 2023
Completion date
February 13, 2024
Enrollment
114 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

alpha-1 antitrypsin deficiency